Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 15, 2014 -- According to the International Atomic ... security comes from terrorists acquiring sufficient quantities of ... a crude nuclear explosive device. The IAEA also ... have involved gram-level quantities, which can be challenging ... to a new study appearing this week in ...
(Date:7/10/2014)... A new study published today in the journal ... has found that time of day and sleep deprivation ... could be crucial when looking at the best time ... and heart disease, and for administering medicines effectively. , ... of Cancer Research, London, investigated the links between sleep ...
(Date:7/10/2014)... batteries that power our laptops and electric vehicles could ... charge with the help of a sponge-like silicon material. ... the graphite traditionally used in one of the battery,s ... energy storage capacity of graphite. A paper describing the ... today in Nature Communications . , "Silicon has ...
(Date:7/10/2014)... recent study by researchers at the University of ... physical mechanisms governing the interplay of spin and ... limits of ultrafast spintronic devices for data storage ... charge as well as spin-angular momentum. In a ... there is no spin current," explained David Cahill, ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3University of Illinois study advances limits for ultrafast nano-devices 2
... Alba Therapeutics Corporation today,announced that its Investigational ... of endogenous insulin production capacity in new-onset,type 1 ... deliberation period,by the U.S. Food and Drug Administration ... study in 2008 while focusing the majority,of its ...
... will review common U.S. laws on research and process labs ... offer practical ... in association with Lab Manager Magazine, will present a Web,conference ... EST. The online conference will review common U.S. federal laws,pertaining ...
... SAN CARLOS, Calif., Sept. 5 NeurogesX, Inc.,(Nasdaq: ... developing novel,pain management therapies, announced today the appointment ... directors. Since May 2006, Mr. Peacock,has been a ... Prior to joining SV Life Sciences, Mr. Peacock ...
Cached Biology Technology:Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 3NeurogesX Appoints New Director to the Board 2NeurogesX Appoints New Director to the Board 3
(Date:7/10/2014)... CORAL SPRINGS, Florida , July 1, 2014 ... smart wallets pave way for convenience and improved security: NXT-ID, ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... ) and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: ... market, is pleased to announce that the second series of ...
(Date:7/10/2014)... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing ... was interviewed on July 1 st on the Downtown ... Mr. Pereira discusses the company,s next generation smart wallet with ... Wocket™ aims to replace a traditional wallet with a new ... tells Gino he has never heard of the Wocket and ...
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... + Lomb, the global eye health company, announced today that ... unowned shares of Technolas ™ Perfect Vision GmbH (TPV), ... was established in 2009 through a joint venture between Bausch ... sell advanced refractive and cataract technologies. The deal is expected ...
... -- Four innovating life science fields to keep an ... and tissue culture. Thanks to an aging population and ... these markets are on the rise. (Photo: ... (GII) presents four innovative life science market research reports ...
... . , Methane is formed under the absence ... the sea floor. It is a much more powerful greenhouse ... this gas is inactivated before it reaches the atmosphere and ... have now proven that these microorganisms are quite picky about ...
Cached Biology News:Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 2Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 3Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 2Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 3Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 4Strange diet for methane consuming microorganisms 2
Handles samples from from 75l to 150l...
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Ubiquitin Related I Sampler Kit 10 mu g each...
DNA Repair Sampler Kit 10g each...
Biology Products: